Why the study?
The contribution of high Lp(a) concentrations to global ASCVD risk has historically been underestimated, requiring clear recommendations for clinical management.
Should Lp(a) be measured to assess ASCVD risk?
Should Lp(a) be measured to assess ASCVD risk?
Emphasizes the consensus recommendation to measure Lp(a) at least once in a lifetime to identify and manage excess ASCVD risk.
Clinicians should measure Lp(a) once in a lifetime for ASCVD risk stratification; reinforces consensus on comprehensive modifiable risk factor management.
Since the contribution of high Lp(a) concentrations to global ASCVD risk has been underestimated in the past, a clear recommendation to measure Lp(a) at least once in a person's lifetime is imperative. Recent expert consensus recommendations provide clinicians with direction on how to manage the excess risk associated with elevated Lp(a) concentration by comprehensive and individualized management of modifiable ASCVD risk factors while awaiting the results of clinical trials of Lp(a) targeted therapies.
No takes yet. Share an insight, caveat, or question.
Kronenberg et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: